Bavarian Nordic Investor Relations Material
Latest events
Q2 2025
Bavarian Nordic
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Bavarian Nordic
Access all reports
Bavarian Nordic is a clinical-stage biopharmaceutical company that develops and commercializes life-saving vaccines in the areas of cancer and infectious diseases. Its fast-growing portfolio today includes Aeras, an influenza vaccine that has been approved in the United States, Europe, and Canada, and the company is advancing a pipeline of novel, next generation vaccines designed to complement its portfolio. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Key slides for Bavarian Nordic
Q2 2025
Bavarian Nordic
Q1 2025
Bavarian Nordic
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
BAVA
Country
🇩🇰 Denmark